Opicapone (Ongentys) is a selective, reversible catechol-O-methyltransferase (COMT) inhibitor, providing an important adjunctive treatment option for "off" episodes in patients with Parkinson’s disease (PD).
Indications for Opicapone (Ongentys)
Primary Indications
Adjunctive Treatment for "Off" Episodes in Parkinson’s Disease: Used in combination with levodopa/carbidopa, it is indicated for Parkinson’s disease patients experiencing "off" episodes.
By inhibiting the COMT enzyme, opicapone reduces the metabolism of levodopa and extends its therapeutic effect, thereby improving motor fluctuation symptoms.
Key Limitations
It is only suitable for patients already on a levodopa/carbidopa regimen and cannot be used alone.
It is contraindicated in patients concurrently using non-selective monoamine oxidase (MAO) inhibitors or those with catecholamine-secreting tumors such as pheochromocytoma.
Specifications and Properties of Opicapone (Ongentys)
Dosage Specifications
50mg Capsules: Dark blue opaque caps and dark pink opaque bodies. Both the capsule bodies and caps are axially imprinted with "OPC" and "50" in white.
25mg Capsules: Light blue opaque caps and light pink opaque bodies. Imprinted with "OPC" and "25" in blue.
Composition
Active Ingredient: Opicapone.
Excipients: Lactose, magnesium stearate, pregelatinized starch, etc. The capsule shell contains FD&C dyes, gelatin, and titanium dioxide.
Property Characteristics
Opicapone is a yellow powder or crystalline solid with limited water solubility, and must be administered orally.
Storage Methods for Opicapone (Ongentys)
Storage Conditions
Temperature Requirement: Store in an environment below 30°C (86°F) to avoid exposure to high temperatures.
Packaging Description: The medication is supplied in bottles with child-resistant caps.
Other Relevant Tips
Store the medication in a dry place to avoid moisture.
Keep the original packaging intact to prevent the capsules from light exposure or physical damage.
